| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 1930- | TQ, | Therapeutic implications and clinical manifestations of thymoquinone |
| - | Review, | Var, | NA |
| 1933- | TQ, | Thymoquinone: potential cure for inflammatory disorders and cancer |
| - | Review, | Var, | NA |
| 1935- | TQ, | Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis |
| - | Review, | OS, | NA |
| 2350- | UA, | Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1020- | UA, | Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 5017- | UA, | Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells |
| - | in-vitro, | Cerv, | INT-407 | - | in-vitro, | CRC, | HCT116 |
| 5019- | UA, | Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions |
| - | Review, | Var, | NA |
| 5020- | UA, | Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway |
| - | in-vitro, | Ovarian, | NA |
| 5021- | UA, | Anticancer effect of ursolic acid via mitochondria-dependent pathways |
| - | Review, | Var, | NA |
| 5022- | UA, | Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks |
| - | Review, | Var, | NA |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4862- | Uro, | Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease |
| - | in-vivo, | AD, | NA | - | in-vitro, | Nor, | PC12 |
| 4870- | Uro, | Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 4871- | Uro, | DHA, | LT, | A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 4878- | Uro, | Activation of the Gut–Brain Interaction by Urolithin A and Its Molecular Basis |
| - | Review, | AD, | NA |
| 4856- | Uro, | Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro |
| - | in-vitro, | NPC, | CNE1 | - | in-vitro, | NPC, | CNE2 |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4835- | Uro, | Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway |
| - | in-vitro, | SCC, | NA |
| 4837- | Uro, | Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review |
| - | Review, | Var, | NA |
| 4839- | Uro, | Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | LNCaP |
| 4840- | Uro, | Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 4841- | Uro, | Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 4846- | Uro, | Urolithin A exerts anti-tumor effects on gastric cancer via activating autophagy-Hippo axis and modulating the gut microbiota |
| - | in-vivo, | GC, | NA |
| 4847- | Uro, | Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells |
| - | in-vitro, | CRC, | SW-620 |
| 4849- | Uro, | Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway |
| - | vitro+vivo, | GC, | NA |
| 4852- | Uro, | Dietary Urolithin B Suppresses Lung Tumorigenesis Correlating with Autophagy Induction and Gut Microbiota Remodeling |
| - | vitro+vivo, | Lung, | NA |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
| 4854- | Uro, | Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC) |
| - | Review, | Pca, | NA |
| 4033- | VitB3, | Can nicotinamide riboside protect against cognitive impairment? |
| - | in-vivo, | AD, | NA |
| 1836- | VitC, | VitK3, | Chemo, | Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib |
| - | in-vitro, | AML, | NA |
| 610- | VitC, | Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues |
| - | in-vitro, | lymphoma, | JPL119 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | NA |
| 599- | VitC, | Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment |
| - | Review, | NA, | NA |
| 633- | VitC, | Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment |
| - | Analysis, | NA, | NA |
| 631- | VitC, | Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 |
| - | vitro+vivo, | Liver, | NA |
| 3139- | VitC, | Vitamin C and sodium bicarbonate enhance the antioxidant ability of H9C2 cells and induce HSPs to relieve heat stress |
| - | in-vitro, | Nor, | H9c2 |
| 3142- | VitC, | Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF12A |
| 3109- | VitC, | Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway |
| - | in-vitro, | Lung, | H1299 |
| 4618- | VitD3, | Vitamin D sensitizes cervical cancer to radiation-induced apoptosis by inhibiting autophagy through degradation of Ambra1 |
| - | in-vivo, | Cerv, | NA |
| 2366- | VitD3, | Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 4309- | VitK2, | Vitamins in the Prevention and Support Therapy of Neurodegenerative Diseases |
| - | Review, | NA, | NA |
| 2274- | VitK2, | Vitamin K2 Modulates Mitochondrial Dysfunction Induced by 6-Hydroxydopamine in SH-SY5Y Cells via Mitochondrial Quality-Control Loop |
| - | in-vitro, | Nor, | SH-SY5Y |
| 1817- | VitK2, | Research progress on the anticancer effects of vitamin K2 |
| - | Review, | Var, | NA |
| 1824- | VitK2, | Vitamin K and its analogs: Potential avenues for prostate cancer management |
| - | Review, | Pca, | NA |
| 1816- | VitK2, | Role of Vitamin K in Selected Malignant Neoplasms in Women |
| - | Review, | Var, | NA |
| 1822- | VitK2, | Vitamin K: A novel cancer chemosensitizer |
| - | Review, | Var, | NA |
| 1840- | VitK2, | The mechanisms of vitamin K2-induced apoptosis of myeloma cells |
| - | in-vitro, | Melanoma, | NA |
| 1838- | VitK3, | PDT, | Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways |
| - | in-vitro, | Cerv, | NA |
| 1839- | VitK3, | Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1756- | WBV, | Low-frequency mechanical vibration induces apoptosis of A431 epidermoid carcinoma cells |
| - | in-vitro, | MB, | A431 |
| 5015- | Xan, | PEITC, | Comparison of the Impact of Xanthohumol and Phenethyl Isothiocyanate and Their Combination on Nrf2 and NF-κB Pathways in HepG2 Cells In Vitro and Tumor Burden In Vivo |
| - | in-vitro, | HCC, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid